Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.

The Journal of pathology - 1 Sept 1998

Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A

Abstract excerpt

Two molecular pathways leading to cancer are known. Common-type cancers arise from the 'tumour suppressor' pathway, characterized by gross chromosomal changes and allelic losses (LOH) in an average of 25 per cent or more of randomly chosen chromosomal loci. The 'mutator pathway' has been recognized in a subset of cancers, characterized by widespread microsatellite DNA instability and rarity of chromosomal losses....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Genes, p53

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, ras

Share to Immunohistochemistry

Share to Microsatellite Repeats

Share to Mutation

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 9875139
DOI: 10.1002/(SICI)1096-9896(199809)186:1<41::AID-PATH172>3.0.CO;2-L

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.PMID 9875139Read ↗

Deletion of 17p in cancers: Guilt by (p53) associationSemantic proximity Read ↗

Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.Semantic proximity Read ↗

Molecular genetic changes in human epithelial ovarian malignancies.Semantic proximity Read ↗

Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.Semantic proximity Read ↗

Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.Semantic proximity Read ↗

Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.Semantic proximity Read ↗

Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progressionSemantic proximity Read ↗

Human gastric adenocarcinoma allelotype on chromosomes 17 and 18.Semantic proximity Read ↗

Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumorsSemantic proximity Read ↗

Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors.Semantic proximity Read ↗

Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas.Semantic proximity Read ↗

Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.